1. Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98 
J. Robert, E. Cambau, K. Grenet, D. Trystram, Y. Péan, M.-H. Fiévet, V. Jarlier 
Clinical Microbiology and Infection 
Volume 7, Issue 10, Pages (October 2001)
DOI: /j x x
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

2. Figure 1
Distribution (%) of the inhibition zone diameters for nalidixic acid against all Escherichia coli strains (a) and for ciprofloxacin against Escherichia coli strains resistant to nalidixic acid (b).
Clinical Microbiology and Infection 2001 7, DOI: ( /j x x)
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

3. Figure 2
Distribution (%) of the minimal inhibitory concentrations (MICs) of ciprofloxacin against nalidixic acid-resistant Escherichia coli (a) and K. pneumoniae (b).
Clinical Microbiology and Infection 2001 7, DOI: ( /j x x)
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions